Premium
Efficacy, toxicity and cost analysis for non‐platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum‐based chemotherapy in IIIB/IV non‐small‐cell lung cancer: single‐institution experience
Author(s) -
TADA H.,
MATSUI S.,
KAWAHARA M.,
HOSOE S.,
HAMADA C.,
FUKUSHIMA M.
Publication year - 2008
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2007.00816.x
Subject(s) - gemcitabine , docetaxel , vinorelbine , medicine , regimen , oncology , chemotherapy , cisplatin , neutropenia , lung cancer , carboplatin , nausea , gastroenterology
A new non‐platinum sequential triplet combination chemotherapy regimen, comprising gemcitabine (1000 mg/m 2 ) and vinorelbine (25 mg/m 2 ), followed by docetaxel (60 mg/m 2 ), was compared in terms of efficacy, toxicity and cost with platinum‐based chemotherapy regimens (comprising cisplatin plus one or more other anti‐tumour drugs) for the treatment of advanced non‐small‐cell lung cancer in a matched, small‐sample size, case–control study. Patients were selected from a single institution. Patients in the platinum and non‐platinum groups were matched for clinical stage (IIIB/IV), performance status (0/1), age and sex. For the non‐platinum and platinum groups, the overall response rates were 40% and 47%, and the median survival times were 14 and 14.5 months respectively. The most common grade 3–4 toxicity was neutropenia (27%) in the non‐platinum group and nausea/vomiting (67%) in the platinum group. The total treatment cost did not differ significantly between the two groups. The non‐platinum sequential triplet combination chemotherapy regimen studied was shown to be as effective as the traditional cisplatin‐based combination chemotherapy regimen, and was associated with less toxicity.